Work

A phase 2 study of the OX40 agonist BGB-A445, in combination with docetaxel or BGB-15025, an HPK1 inhibitor, in patients with NSCLC pretreated by anti-PD-(L)1 antibodies.

Year: 2025

Type: article

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e14513

Authors: Tae Min Kim, Haiyan Liu, Byoung Chul Cho, Youngjoo Lee, Byoung Yong Shim, Fang Ma, Mingjuan Zhang, Jianchun Duan, Hongling Li, Ramil Abdrashitov, Zhaoyin Zhu, Hugh Giovinazzo, Ye Zhao, Yajie Guo, Jie Wang

Institutions: Seoul National University Hospital, Shandong First Medical University, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, National Cancer Center, The Catholic University of Korea St. Vincent's Hospital, Second Xiangya Hospital of Central South University, Weihai Municipal Hospital, Shanxi Provincial Cancer Hospital, Gansu Provincial Hospital, BeOne Medicines (Switzerland), Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: BeiGene

OpenAlex ID: W4410804577

FWCI: 0.371

Cites:

Cited by: 1

Related to: 10